ARDELYX, INC. Proceeds from Sale and Maturity of Debt Securities, Available-for-sale
ARDELYX, INC. (ARDX) reported Proceeds from Sale and Maturity of Debt Securities, Available-for-sale of $94.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities · last filed 2026-08-06
- ARDELYX, INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2026-06-30 was $56.56M, a 3.12% decline year-over-year.
- ARDELYX, INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2026-03-31 was $37.95M, a 9.28% increase year-over-year.
- ARDELYX, INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2025-12-31 was $55.00M, a 4.35% decline year-over-year.
- ARDELYX, INC. proceeds from sale and maturity of debt securities, available-for-sale for the quarter ending 2025-09-30 was $63.35M, a 49.96% increase year-over-year.
- ARDELYX, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2025 was $211.46M, a 18.89% increase from fiscal 2024.
- ARDELYX, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2024 was $177.85M, a 110.92% increase from fiscal 2023.
- ARDELYX, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2023 was $84.32M, a 25.85% increase from fiscal 2022.
- ARDELYX, INC. proceeds from sale and maturity of debt securities, available-for-sale for fiscal 2022 was $67.00M, a 46.63% decline from fiscal 2021.
| Period end | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 3 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 6 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 9 month | Proceeds from Sale and Maturity of Debt Securities, Available-for-sale 12 month |
|---|---|---|---|---|
| 2026-06-30 | $56.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $94.51M 10-Q · filed 2026-08-06 | $149.51M derived: sum of 3 quarters · filed 2026-08-06 | $212.86M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $37.95M 10-Q · filed 2026-04-30 | $92.95M derived: sum of 2 quarters · filed 2026-04-30 | $156.30M derived: sum of 3 quarters · filed 2026-04-30 | $214.68M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $55.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $118.35M derived: sum of 2 quarters · filed 2026-02-19 | $176.73M derived: sum of 3 quarters · filed 2026-08-06 | $211.46M 10-K · filed 2026-02-19 |
| 2025-09-30 | $63.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $121.73M derived: sum of 2 quarters · filed 2026-08-06 | $156.46M 10-Q · filed 2025-10-30 | $213.96M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $58.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $93.11M 10-Q · filed 2026-08-06 | $150.61M derived: sum of 3 quarters · filed 2026-08-06 | $192.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $34.73M 10-Q · filed 2026-04-30 | $92.23M derived: sum of 2 quarters · filed 2026-04-30 | $134.47M derived: sum of 3 quarters · filed 2026-04-30 | $180.98M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | $57.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $99.74M derived: sum of 2 quarters · filed 2026-02-19 | $146.25M derived: sum of 3 quarters · filed 2026-02-19 | $177.85M 10-K · filed 2026-02-19 |
| 2024-09-30 | $42.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $88.75M derived: sum of 2 quarters · filed 2025-10-30 | $120.35M 10-Q · filed 2025-10-30 | $168.41M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-06-30 | $46.51M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | $78.11M 10-Q · filed 2025-08-04 | $126.17M derived: sum of 3 quarters · filed 2026-02-19 | $143.18M derived: sum of 4 quarters · filed 2026-02-19 |
| 2024-03-31 | $31.60M 10-Q · filed 2025-05-01 | $79.66M derived: sum of 2 quarters · filed 2026-02-19 | $96.67M derived: sum of 3 quarters · filed 2026-02-19 | $104.92M derived: sum of 4 quarters · filed 2026-02-19 |
| 2023-12-31 | $48.06M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-19 | $65.07M derived: sum of 2 quarters · filed 2026-02-19 | $73.32M derived: sum of 3 quarters · filed 2026-02-19 | $84.32M 10-K · filed 2026-02-19 |
| 2023-09-30 | $17.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-10-31 | $25.26M derived: sum of 2 quarters · filed 2024-10-31 | $36.26M 10-Q · filed 2024-10-31 | $44.26M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-06-30 | $8.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | $19.25M 10-Q · filed 2024-08-01 | $27.25M derived: sum of 3 quarters · filed 2025-02-20 | $43.95M derived: sum of 4 quarters · filed 2025-02-20 |
| 2023-03-31 | $11.00M 10-Q · filed 2024-05-02 | $19.00M derived: sum of 2 quarters · filed 2025-02-20 | $35.70M derived: sum of 3 quarters · filed 2025-02-20 | $50.70M derived: sum of 4 quarters · filed 2025-02-20 |
| 2022-12-31 | $8.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-20 | $24.70M derived: sum of 2 quarters · filed 2025-02-20 | $39.70M derived: sum of 3 quarters · filed 2025-02-20 | $67.00M 10-K · filed 2025-02-20 |
| 2022-09-30 | $16.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-10-31 | $31.70M derived: sum of 2 quarters · filed 2023-10-31 | $59.00M 10-Q · filed 2023-10-31 | $81.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $42.30M 10-Q · filed 2023-08-02 | $64.30M derived: sum of 3 quarters · filed 2024-02-22 | $107.30M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $27.30M 10-Q · filed 2023-05-03 | $49.30M derived: sum of 2 quarters · filed 2024-02-22 | $92.30M derived: sum of 3 quarters · filed 2024-02-22 | $117.48M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $22.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $65.00M derived: sum of 2 quarters · filed 2024-02-22 | $90.18M derived: sum of 3 quarters · filed 2024-02-22 | $125.55M 10-K · filed 2024-02-22 |
| 2021-09-30 | $43.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $68.18M derived: sum of 2 quarters · filed 2022-11-03 | $103.55M 10-Q · filed 2022-11-03 | $143.88M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-06-30 | $25.18M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $60.55M 10-Q · filed 2022-08-04 | $100.88M derived: sum of 3 quarters · filed 2023-03-02 | $154.76M derived: sum of 4 quarters · filed 2023-03-02 |
| 2021-03-31 | $35.37M 10-Q · filed 2022-05-05 | $75.70M derived: sum of 2 quarters · filed 2023-03-02 | $129.59M derived: sum of 3 quarters · filed 2023-03-02 | $151.10M derived: sum of 4 quarters · filed 2023-03-02 |
| 2020-12-31 | $40.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | $94.22M derived: sum of 2 quarters · filed 2023-03-02 | $115.73M derived: sum of 3 quarters · filed 2023-03-02 | $119.73M 10-K · filed 2023-03-02 |
| 2020-09-30 | $53.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12 | $75.40M derived: sum of 2 quarters · filed 2021-11-12 | $79.40M 10-Q · filed 2021-11-12 | $90.29M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $21.52M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-13 | $25.52M 10-Q · filed 2021-08-13 | $36.40M derived: sum of 3 quarters · filed 2022-02-28 | |
| 2020-03-31 | $4.00M 10-Q · filed 2021-05-06 | $14.88M derived: sum of 2 quarters · filed 2022-02-28 | ||
| 2019-12-31 | $10.88M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $126.37M 10-K · filed 2022-02-28 | ||
| 2019-09-30 | $115.48M 10-Q · filed 2020-11-05 | |||
| 2018-12-31 | $139.45M 10-K · filed 2021-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Avalo Therapeutics, Inc. (AVTX) | United States | $0.842B | -9.74 |
| Immix Biopharma, Inc. (IMMX) | United States | $0.837B | -18.44 |
| Cryoport, Inc. (CYRX) | United States | $0.881B | -21.29 |
| Theravance Biopharma, Inc. (TBPH) | $0.885B | 16.40 | |
| Obsidian Therapeutics, Inc. (OBX) | United States | $0.829B | |
| LEXICON PHARMACEUTICALS, INC. (LXRX) | United States | $0.823B | -17.48 |
| RIGEL PHARMACEUTICALS INC (RIGL) | United States | $0.893B | 2.25 |
| GYRE THERAPEUTICS, INC. (GYRE) | United States | $0.818B | -24.71 |
| Apnimed, Inc. (APMD) | United States | $0.899B | |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |